MergerApr 14, 2026, 09:26 AM
Galera Therapeutics to Merge with Obsidian Therapeutics
AI Summary
Galera Therapeutics, Inc. has entered into a definitive Agreement and Plan of Merger with Obsidian Therapeutics, Inc., Gazelle Parent, Inc., and two merger subsidiaries. Under the agreement, both Galera and Obsidian will merge into separate subsidiaries of Gazelle Parent, Inc., with both companies surviving as wholly owned subsidiaries. The transaction is structured to qualify as a tax-free reorganization for U.S. federal income tax purposes, and Obsidian shareholders will receive shares of Parent Common Stock.
Key Highlights
- Galera Therapeutics, Inc. entered a Merger Agreement on April 14, 2026.
- Galera will merge into Galera Merger Sub, becoming a wholly owned subsidiary of Parent.
- Obsidian Therapeutics, Inc. will merge into Obsidian Merger Sub, becoming a wholly owned subsidiary of Parent.
- The Mergers are intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.
- Obsidian shares will convert into Parent Common Stock based on an exchange ratio.